联合VEGF和MMP-9检测探寻临床完全缓解上皮性卵巢癌患者的CA125界值  

Explore Cut-Off Value of CA125 in Patients with Epithelial Ovarian Cancers Who Had a Complete Clinical Response Combined with Serum VEGF and MMP-9 Measurement

作　　者：李丹丹[1] 王婷婷[2] 李蜀凤[2] 朴金霞[2] Li Dandan;Wang Tingting;Li Shufeng;Piao Jinxia(Reproductive Medical Center of the Second Hospital of Jilin University,Changchun 130062,China;Tumor Hospital of Jilin Province,Changchun 130021,China)

机构地区：[1]吉林大学第二医院生殖中心,吉林长春130062 [2]吉林省肿瘤医院,吉林长春130021

出　　处：《北华大学学报（自然科学版）》2018年第6期784-787,共4页Journal of Beihua University（Natural Science）

基　　金：吉林省卫生计生适宜技术推广项目(2014S016)

摘　　要：目的联合血清VEGF和MMP-9检测探寻临床完全缓解上皮性卵巢癌患者的CA125界值.方法采集临床完全缓解上皮性卵巢癌患者静脉血,测定各组患者血清CA125,VEGF和MMP-9水平,并对患者进行病情监测和随访.结果以17 U/mL作为CA125分割值,将临床完全缓解上皮性卵巢癌患者分为两组,C1(CA125≤17 U/mL)组2a无瘤生存率较C2(17 U/mL<CA125<35 U/mL)组明显升高,C1组患者血清VEGF,MMP-9水平较C2组明显降低.结论将17 U/mL作为上皮性卵巢癌患者终止治疗的CA125界值,更有利于消灭隐匿病灶,改善上皮性卵巢癌患者的治疗结局.Objective To explore cut-off value of CA125 in patients with epithelial ovarian cancers who had aclinically complete response combined with serum VEGF and MMP-9 measurement. Method Collected venousblood from patients with epithelial ovarian cancers for serum CA125, VEGF and MMP-9. All patients weremonitored and followed up. Results Patients who had a clinically complete response were divided into twogroups according to 17 U/ mL. In the former group（CA125≤17 U/ mL）,two years survival rate without tumor wassignificantly higher than the latter group（17 U/ mL〈CA125〈35 U/ mL）,and the serum VEGF and MMP-9 levelsof C1 group were significantly lower than those of the latter group. Conclusion 17 U/ mL was used as thethreshold of CA125 for patients with epithelial ovarian cancer,it is better to eliminate hidden lesions and improvethe treatment outcome of patients with epithelial ovarian cancer.

关 键 词：上皮性卵巢癌 CA125 VEGF MMP-9 2a无瘤生存率 

分 类 号：R737.71[医药卫生—肿瘤]